Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level-Reference-Cited by-同舟云学术

Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level

Published:2021-01-15 Issue:2 Volume:60 Page:191-199
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Hino Naoyuki¹²,Sasaki Ryu¹,Takahashi Youichi³,Koike Makiko³,Fukushima Masanori¹,Haraguchi Masafumi¹,Honda Takuya¹,Miuma Satoshi¹,Ozawa Eisuke¹,Miyaaki Hisamitsu¹,Ichikawa Tatsuki²³⁴,Nakao Kazuhiko¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan

2. Department of Comprehensive Community Care Systems, Nagasaki University Graduate School of Biomedical Sciences, Japan

3. Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Japan

4. Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/60/2/60_5563-20/_pdf

Reference34 articles.

1. 1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.

2. 2. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins - impact for the viral life cycle and pathogenesis of liver disease. Viruses 5: 1292-1324, 2013.

3. 3. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59: 2083-2091, 2014.

4. 4. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 15: 645-653, 2015.

5. 5. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 21: 762-768, 2014.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis;Lipids in Health and Disease;2024-03-09

2. Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review;Liver International;2024-02-22